TW579299B - Transdermal therapeutic system containing the free base of a D2 agonist, and a process for its production - Google Patents

Transdermal therapeutic system containing the free base of a D2 agonist, and a process for its production Download PDF

Info

Publication number
TW579299B
TW579299B TW088104112A TW88104112A TW579299B TW 579299 B TW579299 B TW 579299B TW 088104112 A TW088104112 A TW 088104112A TW 88104112 A TW88104112 A TW 88104112A TW 579299 B TW579299 B TW 579299B
Authority
TW
Taiwan
Prior art keywords
patent application
item
scope
ethyl
transdermal therapeutic
Prior art date
Application number
TW088104112A
Other languages
English (en)
Chinese (zh)
Inventor
Walter Muller
James V Peck
Original Assignee
Lohmann Therapie Syst Lts
Aderis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7862904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW579299(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lohmann Therapie Syst Lts, Aderis Pharmaceuticals Inc filed Critical Lohmann Therapie Syst Lts
Application granted granted Critical
Publication of TW579299B publication Critical patent/TW579299B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW088104112A 1998-03-30 1999-07-17 Transdermal therapeutic system containing the free base of a D2 agonist, and a process for its production TW579299B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19814084A DE19814084B4 (de) 1998-03-30 1998-03-30 D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung

Publications (1)

Publication Number Publication Date
TW579299B true TW579299B (en) 2004-03-11

Family

ID=7862904

Family Applications (1)

Application Number Title Priority Date Filing Date
TW088104112A TW579299B (en) 1998-03-30 1999-07-17 Transdermal therapeutic system containing the free base of a D2 agonist, and a process for its production

Country Status (30)

Country Link
US (4) US6884434B1 (,)
EP (1) EP1033978B1 (,)
JP (1) JP3984785B2 (,)
KR (1) KR100432276B1 (,)
CN (1) CN1142773C (,)
AR (1) AR014778A1 (,)
AT (1) ATE210973T1 (,)
AU (1) AU746856B2 (,)
BR (1) BRPI9909313B8 (,)
CA (1) CA2326630C (,)
CZ (1) CZ297889B6 (,)
DE (4) DE19814084B4 (,)
DK (1) DK1033978T3 (,)
ES (1) ES2170573T3 (,)
FR (1) FR06C0025I2 (,)
HU (1) HU226733B1 (,)
ID (1) ID26646A (,)
IL (1) IL138722A (,)
LU (1) LU91269I2 (,)
MY (1) MY119660A (,)
NL (1) NL300236I2 (,)
NO (3) NO325766B1 (,)
NZ (1) NZ507066A (,)
PL (1) PL193074B1 (,)
PT (1) PT1033978E (,)
SK (1) SK284618B6 (,)
TR (1) TR200002829T2 (,)
TW (1) TW579299B (,)
WO (1) WO1999049852A1 (,)
ZA (1) ZA200005261B (,)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE19918106A1 (de) * 1999-04-22 2000-10-26 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit neutralisierten Acrylathaftklebern
MXPA02000118A (es) 1999-07-02 2003-02-27 Lohmann Therapie Syst Lts Sistema de microdepositos a base de polisiloxanos y solventes ambifilos.
NZ519069A (en) * 1999-11-29 2004-06-25 Lohmann Therapie Syst Lts Transdermal therapeutic systems having improved stability and their production
DE10054713C2 (de) * 1999-11-29 2002-07-18 Lohmann Therapie Syst Lts Transdermale Therapeutische Systeme mit verbesserter Stabilität und ein Verfahren zu ihrer Herstellung
DE10012908B4 (de) * 2000-03-16 2005-03-17 Lts Lohmann Therapie-Systeme Ag Stabilisierte übersättigte transdermale therapeutische Matrixsysteme und Verfahren zu ihrer Herstellung
AR030557A1 (es) 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US6306403B1 (en) * 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
AU2005242160B2 (en) * 2000-10-12 2009-02-26 Lts Lohmann Therapie-Systeme Ag Improved transdermal therapeutic system for the treatment of parkinson's disease
US20030027793A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal treatment of parkinson's disease
SI1256340T1 (en) * 2001-05-08 2003-12-31 Schwarz Pharma Ag Improved transdermal therapeutic system for the treatment of Parkinson's disease
EP1344522A1 (en) * 2001-05-08 2003-09-17 Schwarz Pharma Ag Transdermal therapeutic system for Parkinson's disease inducing high plasma levels of rotigotine
US20030026830A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
DE10137082A1 (de) 2001-07-28 2003-02-13 Hexal Ag Matrixkontrolliertes transdermales therapeutisches System zur Anwendung von Pramiprexol und Ropinirol
DE10141652B4 (de) * 2001-08-24 2011-04-07 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System auf der Basis von Polyacrylat-Haftklebern ohne funktionelle Gruppen und seine Verwendung
DE10159745A1 (de) 2001-12-05 2003-07-03 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit verbessertem Langzeittragekomfort
US20060263419A1 (en) * 2002-03-12 2006-11-23 Hans-Michael Wolff Transdermal therapeutic system for Parkinson's Disease
DE10220230A1 (de) * 2002-05-06 2003-11-27 Sanol Arznei Schwarz Gmbh Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
EP1386605A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine
EP1386604A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system
US8246979B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
DK1426049T3 (da) * 2002-12-02 2005-08-22 Sanol Arznei Schwarz Gmbh Iontophoretisk tilförsel af rotigotin til behandling af Parkinsons sygdom
DE10261696A1 (de) 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
DE502004001897D1 (de) * 2003-02-07 2006-12-14 Lohmann Therapie Syst Lts Für die wärmeanwendung zur beschleunigung der permeation von wirkstoffen geeignetes transdermales therapeutisches system und seine verwendung
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
DE10334188B4 (de) 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10359528A1 (de) 2003-12-18 2005-07-28 Schwarz Pharma Ag (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
EP1547592A1 (en) 2003-12-23 2005-06-29 Schwarz Pharma Ag Intranasal formulation of rotigotine
DE10361258A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
US20050197385A1 (en) * 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
WO2006039532A2 (en) * 2004-09-29 2006-04-13 Schwarz Pharma, Inc. Transdermal therapeutic system for parkinson’s disease
CA2548864C (en) 2005-06-06 2012-12-11 Nitto Denko Corporation Percutaneous absorption-type pharmaceutical preparation
JP5025998B2 (ja) * 2005-06-06 2012-09-12 日東電工株式会社 経皮吸収製剤
TWI392670B (zh) * 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途
DE102006028987A1 (de) 2006-06-24 2007-12-27 Lts Lohmann Therapie-Systeme Ag Ultraschallverstärktes transdermales therapeutisches System
DE102006054732B4 (de) * 2006-11-21 2010-12-30 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit Ionenpaar-Mikroreservoiren
EP1987815A1 (en) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
CN101147739B (zh) * 2007-07-06 2010-12-08 北京康倍得医药技术开发有限公司 含罗替戈汀的组合物及其制药用途以及含该组合物的透皮贴剂
WO2009063171A1 (en) * 2007-11-16 2009-05-22 Pliva Hrvatska D.O.O. Novel rotigotine salts
WO2009068520A2 (en) 2007-11-28 2009-06-04 Schwarz Pharma Ag Polymorphic form of rotigotine
ES2648197T3 (es) * 2008-02-27 2017-12-29 Hisamitsu Pharmaceutical Co., Inc. Parche medicado
WO2009107478A1 (ja) 2008-02-27 2009-09-03 久光製薬株式会社 貼付剤及び包装体
DE102008013701A1 (de) * 2008-03-11 2009-09-17 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System mit stabilisierter Membran
US20090247537A1 (en) * 2008-03-25 2009-10-01 William Dale Overfield Methods for preventing or treating bruxism using dopaminergic agents
JPWO2009139213A1 (ja) * 2008-05-15 2011-09-15 日本臓器製薬株式会社 プロクロルペラジン含有外用医薬組成物
DE102008060203A1 (de) 2008-12-07 2010-06-10 Dietrich Wilhelm Schacht Wirkstoffstabilisierende flächenförmige Vorrichtung
EP2201941A1 (de) * 2008-12-29 2010-06-30 UCB Pharma GmbH Pflaster-Herstellungstechnologie
DE102009022915A1 (de) * 2009-05-27 2010-12-09 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit gesteuertem Wirkstofffluss
EP2281559A1 (en) 2009-06-26 2011-02-09 UCB Pharma GmbH Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis
EP2490673A2 (en) * 2009-10-19 2012-08-29 Actavis Group Ptc Ehf Amorphous rotigotine co-precipitates
EP2338873A1 (en) 2009-12-22 2011-06-29 Gmeiner, Peter New aminotetraline derivatives
CN102665699A (zh) 2009-12-22 2012-09-12 优时比制药有限公司 用于使非结晶形式的罗替戈汀的固体分散体稳定化的聚乙烯吡咯烷酮
EP2457565A1 (de) 2010-11-29 2012-05-30 Ratiopharm GmbH Transdermales therapeutisches System enthaltend Rotigotin
EP2646009A1 (en) 2010-12-02 2013-10-09 Ratiopharm GmbH Rotigotine ionic liquid
WO2012084969A1 (en) 2010-12-22 2012-06-28 Hexal Ag Adhesive composition containing rotigotine and transdermal therapeutic system comprising the adhesive composition
WO2013020527A1 (en) 2011-08-11 2013-02-14 University Of Veterinary And Pharmaceutical Sciences Brno Faculty Of Pharmacy Utilization of alaptide as transdermal penetration modifier in pharmaceutical compositions for human and veterinary applications containing anti-inflammatory drugs and/or antimicrobial chemotherapeutics
EP2559435A1 (en) 2011-08-19 2013-02-20 UCB Pharma GmbH Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke
CN102499906B (zh) * 2011-10-12 2013-04-17 长春健欣生物医药科技开发有限公司 一种罗替戈汀盐酸盐或自由碱成膜凝胶制剂及其制备方法
DE102012013421A1 (de) 2012-07-03 2014-01-09 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System (TTS) mit Rotigotin
DE102011119043A1 (de) 2011-11-22 2013-05-23 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System (TDS) mit Rotigotin
WO2013075822A1 (en) 2011-11-22 2013-05-30 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermal therapeutic system (tts) with rotigotine
DE102012013439A1 (de) 2012-07-03 2014-01-23 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System umfassend Rotigotin und Kristallisationsinhibitor
DE102011090178A1 (de) * 2011-12-30 2013-07-04 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit geringer Neigung zur Spontankristallisation
DE102012205493A1 (de) * 2012-04-03 2013-10-10 Acino Ag Einen Dopamin-Agonisten enthaltendes transdermales Applikationssystem
AU2013285733B2 (en) 2012-07-05 2016-11-10 Sk Chemicals Co., Ltd. Transdermally absorbable preparation containing rotigotine
KR101558043B1 (ko) * 2012-07-06 2015-10-07 에스케이케미칼주식회사 로티고틴 함유 경피흡수제제
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
WO2014198422A1 (de) 2013-06-14 2014-12-18 Tesa Labtec Gmbh Transdermales therapiesystem (tts) mit rotigotin
JP6726096B2 (ja) 2013-07-03 2020-07-22 エルテーエス ローマン テラピー−システメ アーゲー 電子部品を有する経皮治療システム
CA2948219C (en) 2014-05-20 2023-04-04 Lts Lohmann Therapie-Systeme Ag Method for adjusting the release of active agent in a transdermal delivery system
EP3145502B1 (en) 2014-05-20 2022-07-06 LTS Lohmann Therapie-Systeme AG Transdermal delivery system containing rotigotine
ES2954087T3 (es) 2014-05-20 2023-11-20 Lts Lohmann Therapie Systeme Ag Sistema de administración transdérmica que incluye un mediador de interfase
KR102364378B1 (ko) 2014-05-21 2022-02-16 에스케이케미칼 주식회사 안정성을 향상시킨 로티고틴 함유 경피흡수제제
US10011629B2 (en) 2015-05-01 2018-07-03 Cocrystal Pharma, Inc. Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
TWI754702B (zh) 2016-12-28 2022-02-11 德商Ｕｃｂ製藥有限公司 （氮雜）吲哚－和苯並呋喃－３－磺醯胺類
CN109806243B (zh) * 2017-11-20 2022-07-15 北京泰德制药股份有限公司 一种含有氟吡汀或其药用盐的皮肤外用贴剂
ES2988819T3 (es) 2017-12-19 2024-11-21 Hisamitsu Pharmaceutical Co Parche que contiene rotigotina
TWI857957B (zh) 2018-06-19 2024-10-11 德商Ｕｃｂ製藥有限公司 吡啶基及吡基-（氮）吲哚磺醯胺
EP3584244A1 (en) 2018-06-20 2019-12-25 UCB Pharma GmbH Substituted alkoxypyridinyl indolsulfonamides
KR102731700B1 (ko) 2018-10-24 2024-11-15 에스케이케미칼 주식회사 비결정 로티고틴 함유 조성물 및 이의 제조 방법
CN113453676B (zh) 2019-02-15 2025-08-05 久光制药株式会社 罗替戈汀稳定化方法
BR112021024310A2 (pt) 2019-06-05 2022-02-15 Univ Emory Peptidomiméticos para o tratamento de infecções por coronavírus e picornavírus
CN113950356B (zh) 2019-06-14 2024-12-31 久光制药株式会社 含罗替戈汀的贴附剂
JP7631235B2 (ja) 2019-06-17 2025-02-18 ウーツェーベー ファルマ ゲーエムベーハー 多発性硬化症のようなｃｎｓ障害を治療するためのｇｐｒ１７モジュレーターとしてのｎ‐（フェニル）‐インドール‐３‐スルホンアミド誘導体及び関連化合物
PL3854388T3 (pl) 2020-01-24 2024-02-26 Luye Pharma Switzerland Ag Transdermalny system terapeutyczny z substancją czynną rotygotyną i co najmniej jednym klejem silikonowym nieodpornym na działanie amin
CN113368083A (zh) * 2021-06-16 2021-09-10 华健医疗(深圳)有限公司 一种大麻二酚cbd透皮给药系统
JP7322324B1 (ja) 2022-02-21 2023-08-07 久光製薬株式会社 ロチゴチン含有貼付剤
WO2023157865A1 (ja) 2022-02-21 2023-08-24 久光製薬株式会社 ロチゴチン含有貼付剤
CN120282781A (zh) 2022-12-01 2025-07-08 久光制药株式会社 含有罗替戈汀的贴附剂及罗替戈汀稳定性提升方法
WO2024144130A1 (ko) 2022-12-26 2024-07-04 환인제약 주식회사 경피흡수용 제제 및 이의 제조 방법

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5177112A (en) 1983-01-03 1993-01-05 Whitby Research, Inc. Substituted 2-aminotetralins
US5268385A (en) 1983-01-03 1993-12-07 Whitby Research, Inc. Method for treating schizophrenia
US4655767A (en) 1984-10-29 1987-04-07 Dow Corning Corporation Transdermal drug delivery devices with amine-resistant silicone adhesives
US4863970A (en) 1986-11-14 1989-09-05 Theratech, Inc. Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols
US5273757A (en) 1987-09-01 1993-12-28 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Apparatus for the delivery of substances, processes for the production thereof and use thereof
US4915950A (en) 1988-02-12 1990-04-10 Cygnus Research Corporation Printed transdermal drug delivery device
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US4942037A (en) 1988-06-02 1990-07-17 Merck & Co., Inc. Transdermal delivery systems
DE3827561C1 (,) 1988-08-13 1989-12-28 Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De
EP0387751B1 (en) * 1989-03-15 1994-06-08 Nitto Denko Corporation Medicated plasters
US4973468A (en) 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
FR2648131B1 (fr) * 1989-06-13 1991-10-18 Oreal Nouveaux derives de tetrahydro -5,6,7,8 naphtalenol-1, leur procede de preparation et leur utilisation en tant qu'agents antioxydants dans des compositions cosmetiques et pharmaceutiques les contenant
US5252335A (en) 1989-07-12 1993-10-12 Cygnus Therapeutic Systems Transdermal administration of lisuride
US5091186A (en) 1989-08-15 1992-02-25 Cygnus Therapeutic Systems Biphasic transdermal drug delivery device
US5124157A (en) 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5252334A (en) 1989-09-08 1993-10-12 Cygnus Therapeutic Systems Solid matrix system for transdermal drug delivery
US5271940A (en) 1989-09-14 1993-12-21 Cygnus Therapeutic Systems Transdermal delivery device having delayed onset
DE3933460A1 (de) 1989-10-06 1991-04-18 Lohmann Therapie Syst Lts Oestrogenhaltiges wirkstoffpflaster
US5147916A (en) 1990-02-21 1992-09-15 Dow Corning Corporation Hot-melt silicone pressure sensitive adhesive composition and related methods and articles
US5246997A (en) 1990-02-21 1993-09-21 Dow Corning Corporation Method of making a hot-melt silicone pressure sensitive adhesive-coated substrate
US5069909A (en) 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US5382569A (en) * 1991-05-16 1995-01-17 Warner-Lambert Company Endotherlin antagonists
US5232702A (en) * 1991-07-22 1993-08-03 Dow Corning Corporation Silicone pressure sensitive adhesive compositons for transdermal drug delivery devices and related medical devices
US5273755A (en) 1991-08-23 1993-12-28 Cygnus Therapeutic Systems Transdermal drug delivery device using a polymer-filled microporous membrane to achieve delayed onset
US5273756A (en) 1991-08-23 1993-12-28 Cygnus Therapeutic Systems Transdermal drug delivery device using a membrane-protected microporous membrane to achieve delayed onset
US5234690A (en) 1991-08-23 1993-08-10 Cygnus Therapeutic Systems Transdermal drug delivery device using an unfilled microporous membrane to achieve delayed onset
EP0601058A4 (en) 1991-08-27 1995-05-31 Cygnus Therapeutic Systems TRANSDERMAL FORMULATIONS FOR PRRAZOSINE ADMINISTRATION.
US5225198A (en) 1991-08-27 1993-07-06 Cygnus Therapeutic Systems Transdermal administration of short or intermediate half-life benzodiazepines
WO1993007842A1 (en) 1991-10-15 1993-04-29 Cygnus Therapeutic Systems Thermal enhancement of transdermal drug administration
WO1993014727A1 (en) 1992-01-31 1993-08-05 Cygnus Therapeutic Systems Transdermal administration of buprenorphine in the form of ion pair complexes
GB9202915D0 (en) 1992-02-12 1992-03-25 Wellcome Found Chemical compounds
CA2142871A1 (en) 1992-08-25 1994-03-03 Jesus Miranda Printed transdermal drug delivery device
US5308625A (en) 1992-09-02 1994-05-03 Cygnus Therapeutic Systems Enhancement of transdermal drug delivery using monoalkyl phosphates and other absorption promoters
US5989586A (en) 1992-10-05 1999-11-23 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
US5462746A (en) * 1992-11-02 1995-10-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Patch for transdermal administration of volatile pharmaceutically active ingredients of chemically basic nature and a process for preparation
DE4301781C2 (de) 1993-01-23 1995-07-20 Lohmann Therapie Syst Lts Nitroglycerinhaltiges Pflaster, Verfahren zu seiner Herstellung und Verwendung
AU7172794A (en) 1993-06-24 1995-01-17 Cygnus Therapeutic Systems Transdermal delivery system package
US5804214A (en) 1993-07-08 1998-09-08 Cygnus, Inc. Monolithic matrix transdermal delivery system for delivering ketorolac tromethamine
US5382596A (en) * 1993-08-05 1995-01-17 Whitby Research, Inc. Substituted 2-aminotetralins
US5554381A (en) 1993-08-09 1996-09-10 Cygnus, Inc. Low flux matrix system for delivering potent drugs transdermally
AU7566994A (en) 1993-08-16 1995-03-14 Cygnus Therapeutic Systems Contact adhesive extends wear time on skin
AU7517794A (en) 1993-08-16 1995-03-14 Cygnus Therapeutic Systems Transdermal delivery system using a combination of permeation enhancers
WO1995024776A2 (en) 1994-03-11 1995-09-14 Philips Electronics N.V. Transmission system for quasi-periodic signals
US5771890A (en) 1994-06-24 1998-06-30 Cygnus, Inc. Device and method for sampling of substances using alternating polarity
CA2193885C (en) 1994-06-24 2003-11-25 Janet Tamada Iontophoretic sampling device and method
GB2290964A (en) 1994-07-08 1996-01-17 Arto Olavi Urtti Transdermal drug delivery system
US6024974A (en) 1995-01-06 2000-02-15 Noven Pharmaceuticals, Inc. Composition and methods for transdermal delivery of acid labile drugs
AU4657896A (en) 1995-01-19 1996-08-07 Cygnus, Inc. Polyisobutylene adhesives containing high TG tackifier for transdermal devices
WO1996022084A2 (en) 1995-01-19 1996-07-25 Cygnus, Inc. Polymer adhesive formulation containing sorbent particles
US5601839A (en) 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
GB9511366D0 (en) * 1995-06-06 1995-08-02 Smithkline Beecham Plc Novel formulations
AU6032696A (en) 1995-06-07 1996-12-30 Cygnus Therapeutic Systems Pressure sensitive acrylate adhesive composition cross-linke d with aluminum acetylacetonate and containing a drug having a reactive aromatic hydroxyl group
JP3534775B2 (ja) 1995-06-07 2004-06-07 オーソ―マクニール ファーマシューティカル，インコーポレイテッド １７−デアセチルノルゲスチマートを単独でまたはエストロゲンと組み合わせて投与するための経皮パッチおよび方法
US6316022B1 (en) 1995-06-07 2001-11-13 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
US5906830A (en) 1995-09-08 1999-05-25 Cygnus, Inc. Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
US5891461A (en) 1995-09-14 1999-04-06 Cygnus, Inc. Transdermal administration of olanzapine
US5902603A (en) 1995-09-14 1999-05-11 Cygnus, Inc. Polyurethane hydrogel drug reservoirs for use in transdermal drug delivery systems, and associated methods of manufacture and use
WO1997009971A2 (en) 1995-09-14 1997-03-20 Cygnus, Inc. High capacity, superabsorbent drug reservoirs for use in transdermal drug delivery systems
US6063398A (en) 1995-09-20 2000-05-16 L'oreal Cosmetic or dermopharmaceutical patch containing, in an anhydrous polymeric matrix, at least one active compound which is, in particular, unstable in oxidizing mediums, and at least one water-absorbing agent
US5807570A (en) * 1995-09-29 1998-09-15 Cygnus, Inc. Transdermal administration of ropinirole and analogs thereof
US5733571A (en) 1995-12-08 1998-03-31 Euro-Celtique, S.A. Transdermal patch for comparative evaluations
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US5843472A (en) 1997-02-28 1998-12-01 Cygnus, Inc. Transdermal drug delivery sytem for the administration of tamsulosin, and related compositions and methods of use
US5879701A (en) 1997-02-28 1999-03-09 Cygnus, Inc. Transdermal delivery of basic drugs using nonpolar adhesive systems and acidic solubilizing agents
DE19814083C2 (de) 1998-03-30 2002-02-07 Lohmann Therapie Syst Lts Verfahren zur Herstellung von transdermalen therapeutischen Systemen unter Verwendung von basischen Alkalimetallsalzen zur Umwandlung von Wirkstoffsalzen in die freien Basen
DE19814084B4 (de) 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DK1053043T3 (da) 1998-05-13 2002-11-18 Cygnus Therapeutic Systems Opsamlingsenheder til transdermale prøveudtagningssystemer
DE19828273B4 (de) 1998-06-25 2005-02-24 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System, enthaltend Hormone und Kristallisationsinhibitoren
DE69913153D1 (de) 1998-09-17 2004-01-08 Cygnus Therapeutic Systems Gerät zum zusammendrücken einer gel/sensor-einheit
FR2792529B1 (fr) 1999-04-26 2001-09-28 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques comprenant des derives de 2-isoxazole-8-aminotetralines
US6465004B1 (en) 1999-06-05 2002-10-15 Noven Pharmaceuticals, Inc. Solubility enhancement of drugs in transdermal drug delivery systems and methods of use
US6218421B1 (en) 1999-07-01 2001-04-17 Smithkline Beecham P.L.C. Method of promoting smoking cessation
DE19940238A1 (de) 1999-08-25 2001-03-01 Lohmann Therapie Syst Lts Wirkstoffhaltiges therapeutisches System zur Applikation auf der Haut mit mindestens zwei polymerhaltigen Schichten
KR100317533B1 (ko) * 1999-11-10 2001-12-24 윤종용 반도체 집적회로 장치에서의 레이저 퓨즈박스의 구조 및그에 따른 제조 방법
CN1185225C (zh) 1999-11-23 2005-01-19 阿德里斯制药公司 制备氮取代的氨基1,2,3,4－四氢化萘的改进方法
NZ519069A (en) 1999-11-29 2004-06-25 Lohmann Therapie Syst Lts Transdermal therapeutic systems having improved stability and their production
US20020110585A1 (en) 1999-11-30 2002-08-15 Godbey Kristin J. Patch therapeutic agent delivery device having texturized backing
DE10018467A1 (de) 2000-04-14 2001-10-25 Bosch Gmbh Robert Elektrische Maschine
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
DE10041479A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
US20020119187A1 (en) 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
DE10060550C1 (de) 2000-12-06 2002-04-18 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit dem Wirkstoff Oxybutynin und Verfahren zur Herstellung Oxybutynin enthaltender Wirkstoffschichten
US20030027793A1 (en) 2001-05-08 2003-02-06 Thomas Lauterback Transdermal treatment of parkinson's disease
US20030026830A1 (en) 2001-05-08 2003-02-06 Thomas Lauterback Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
FR2829028B1 (fr) 2001-08-29 2004-12-17 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de
US20060263419A1 (en) 2002-03-12 2006-11-23 Hans-Michael Wolff Transdermal therapeutic system for Parkinson's Disease
WO2003088958A2 (en) 2002-04-18 2003-10-30 Pharmacia Corporation Combinations of cox-2 inhibitors and other agents for the treatment of parkinson’s disease
US20040048779A1 (en) 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
US20060216336A1 (en) 2002-05-07 2006-09-28 Hans-Michael Wolff Transdermal therapeutic system for Parkinson's Disease
CA2489865C (en) 2002-06-25 2012-05-08 Acrux Dds Pty Ltd Transdermal delivery rate control using amorphous pharmaceutical compositions
DE10234673B4 (de) 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
US8211462B2 (en) 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
US8246980B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
DK1426049T3 (da) 2002-12-02 2005-08-22 Sanol Arznei Schwarz Gmbh Iontophoretisk tilförsel af rotigotin til behandling af Parkinsons sygdom
US9102726B2 (en) 2002-12-04 2015-08-11 Argos Therapeutics, Inc. Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same
DE10261696A1 (de) 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
DE10334188B4 (de) 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10334187A1 (de) 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
US7379762B2 (en) 2003-09-04 2008-05-27 Creative Technology Ltd. Portable digital device orientation
DE10359528A1 (de) 2003-12-18 2005-07-28 Schwarz Pharma Ag (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
EP1547592A1 (en) 2003-12-23 2005-06-29 Schwarz Pharma Ag Intranasal formulation of rotigotine
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
US20050197385A1 (en) 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
TWI392670B (zh) 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途
EP1987815A1 (en) 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
WO2009068520A2 (en) 2007-11-28 2009-06-04 Schwarz Pharma Ag Polymorphic form of rotigotine
EP2281559A1 (en) 2009-06-26 2011-02-09 UCB Pharma GmbH Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis
CN102665699A (zh) 2009-12-22 2012-09-12 优时比制药有限公司 用于使非结晶形式的罗替戈汀的固体分散体稳定化的聚乙烯吡咯烷酮

Also Published As

Publication number Publication date
CN1295470A (zh) 2001-05-16
AU746856C (en) 1999-10-18
FR06C0025I2 (,) 2007-05-25
HUP0101519A2 (hu) 2001-09-28
US10322093B2 (en) 2019-06-18
US7413747B2 (en) 2008-08-19
PL343255A1 (en) 2001-07-30
JP2002509878A (ja) 2002-04-02
DE59900581D1 (de) 2002-01-31
NO325766B1 (no) 2008-07-14
HK1031196A1 (en) 2001-06-08
US20080050424A1 (en) 2008-02-28
US20050033065A1 (en) 2005-02-10
NL300236I2 (nl) 2006-12-01
PT1033978E (pt) 2002-06-28
KR100432276B1 (ko) 2004-05-20
WO1999049852A1 (de) 1999-10-07
DE19814084A1 (de) 1999-10-14
ES2170573T3 (es) 2002-08-01
NO20004915L (no) 2000-11-08
NO2008014I2 (no) 2010-04-19
BR9909313A (pt) 2000-11-21
PL193074B1 (pl) 2007-01-31
KR20010042336A (ko) 2001-05-25
NO2008014I1 (no) 2008-11-03
AU2934199A (en) 1999-10-18
SK284618B6 (sk) 2005-07-01
JP3984785B2 (ja) 2007-10-03
TR200002829T2 (tr) 2001-01-22
BR9909313B1 (pt) 2013-11-12
NZ507066A (en) 2003-01-31
HUP0101519A3 (en) 2002-10-28
CZ20003581A3 (en) 2001-05-16
CZ297889B6 (cs) 2007-04-25
DK1033978T3 (da) 2002-04-15
EP1033978B1 (de) 2001-12-19
NL300236I1 (nl) 2006-10-02
HU226733B1 (en) 2009-08-28
ZA200005261B (en) 2001-05-22
IL138722A0 (en) 2001-10-31
DE122006000035I2 (de) 2009-05-20
IL138722A (en) 2005-11-20
DE19814084B4 (de) 2005-12-22
SK14462000A3 (sk) 2001-04-09
US6884434B1 (en) 2005-04-26
DE122006000035I1 (de) 2006-11-23
NO20080489L (no) 2000-08-11
LU91269I9 (,) 2018-12-31
FR06C0025I1 (,) 2007-04-27
AU746856B2 (en) 2002-05-02
LU91269I2 (fr) 2006-09-26
EP1033978A1 (de) 2000-09-13
ID26646A (id) 2001-01-25
CA2326630C (en) 2006-12-05
US10251844B2 (en) 2019-04-09
NO20004915D0 (no) 2000-09-29
BRPI9909313B8 (pt) 2021-05-25
CA2326630A1 (en) 1999-10-07
AR014778A1 (es) 2001-03-28
MY119660A (en) 2005-06-30
US20080138389A1 (en) 2008-06-12
CN1142773C (zh) 2004-03-24
ATE210973T1 (de) 2002-01-15

Similar Documents

Publication Publication Date Title
TW579299B (en) Transdermal therapeutic system containing the free base of a D2 agonist, and a process for its production
US20040048779A1 (en) Use of rotigotine for treating the restless leg syndrome
JP2004514738A (ja) 活性物質としてオキシブチニンで構成される経皮治療システム
AU774740B2 (en) Microreservoir system on the basis of polysiloxanes and ambiphilic solvents
WO2009006787A1 (en) Composition comprising rotigotine, its use and transdermal patch comprising the composition
JP5000932B2 (ja) ニコチン含有経皮吸収製剤
WO2005099766A1 (ja) 架橋型皮膚用粘着剤
JP2977254B2 (ja) 経皮吸収貼付剤
JPWO2012090322A1 (ja) 貼付剤
JPH11209271A (ja) 経皮吸収製剤
JP2011074035A (ja) 貼付剤
JP3305101B2 (ja) 経皮吸収製剤
JPH11209270A (ja) 経皮吸収製剤
JP5510906B2 (ja) 貼付剤
JPH1112167A (ja) 経皮吸収製剤
JPH09169636A (ja) 貼付剤
JP3251108B2 (ja) 経皮吸収貼付剤
WO1999030702A1 (fr) Preparation a base de levodopa absorbable par voie percutanee
JPH0348620A (ja) 経皮吸収製剤
MXPA00009570A (en) Transdermal therapeutic system which contains a d2 agonist and which is provided for treating parkinsonism, and a method for the production thereof
HK1031196B (en) Transdermal therapeutic system which contains a d2 agonist and which is provided for treating parkinsonism, and a method for the production thereof
JPH08291069A (ja) エペリゾン外用貼付剤
WO1996014069A1 (en) Percutaneously absorbable patch
JPH0348619A (ja) 経皮吸収貼付製剤

Legal Events

Date Code Title Description
MK4A Expiration of patent term of an invention patent